文献速递前列腺增生与排尿功能障碍男科与性医学

良性前列腺梗阻术后勃起功能:系统综述与随机对照试验的网络荟萃分析

Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials.
PubMed 文献 · Eur Urol · 2021-06-12

该系统综述与网络荟萃分析纳入33项RCT(5159例患者,16种干预),评估BPO手术对术后IIEF-5评分的影响。与mTURP相比,前列腺尿道提升术(PUL)在24个月时IIEF-5评分显著改善(MD 3.63,95%CrI 0.14-7.11),其他干预至60个月未见显著差异。

要点

  • PUL在24个月时较mTURP显著改善勃起功能评分(MD 3.63)。
  • 其他BPO干预至60个月对勃起功能无显著差异。
  • 1个月和60个月异质性最高,结论最弱。

核心结论

  • PUL在24个月时较mTURP显著改善勃起功能,但缺乏直接证据。
  • 其他干预至60个月对勃起功能无显著差异。

研究设计与样本

  • 系统综述与随机效应贝叶斯网络荟萃分析,纳入33项RCT、5159例患者、16种干预。

主要发现

  • PUL在1个月(MD 3.88,95%CrI -0.47至8.25;rank p=0.742)、6个月(MD 2.43,95%CrI -0.72至5.62;rank p=0.581)、12个月(MD 2.94,95%CrI -0.26至6.12;rank p=0.782)和24个月(MD 3.63,95%CrI 0.14至7.11;rank p=0.948)排名最高,24个月时达统计学显著。
  • 至60个月其他干预无统计学显著比较,18、48、72个月无法分析。
  • Meta回归中β未达统计学显著,τ²在1个月(0.56)和60个月(0.55)最高。

关键数值与推荐

  • 与mTURP相比,PUL在24个月时IIEF-5评分MD 3.63(95%CrI 0.14-7.11;rank p=0.948)。
  • PUL在1个月MD 3.88(95%CrI -0.47至8.25;rank p=0.742),6个月MD 2.43(95%CrI -0.72至5.62;rank p=0.581),12个月MD 2.94(95%CrI -0.26至6.12;rank p=0.782)。

临床怎么用

  • 对关注勃起功能的BPO患者,PUL在24个月时可能优于mTURP,但需考虑证据直接性不足。
  • 其他BPO干预至60个月对勃起功能影响无显著差异。
  • 建议开展更多比较性功能结局的RCT,如PUL与钬激光或双极剜除术。

局限性

  • 缺乏PUL与mTURP的直接证据。
  • 1个月和60个月异质性最高,结论最弱。
  • 18、48、72个月无法进行网络荟萃分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Benign prostatic obstruction (BPO) is associated with sexual dysfunction. Furthermore, numerous BPO interventions may themselves impact sexual function. OBJECTIVE: To perform a systematic review with network meta-analysis to evaluate how BPO interventions affect erectile function. EVIDENCE ACQUISITION: Three databases were searched for randomised controlled trials (RCTs) comparing surgical interventions for BPO. The primary outcome was postoperative International Index of Erectile Function-5 (IIEF-5) score at ten time points up to 72 mo. A random-effects Bayesian network meta-analysis with meta-regression was performed. In comparison to monopolar transurethral resection (mTURP), the mean difference (MD) with 95% credible interval (CrI) and rank probability (rank p) were calculated for interventions. The mean baseline score was studied in meta-regression. τ2 values were used to quantify heterogeneity. EVIDENCE SYNTHESIS: A total of 48 papers (33 RCTs, 5159 patients, 16 interventions) were included. Prostatic urethral lift (PUL) ranked highest at 1 mo (MD 3.88, 95% CrI -0.47 to 8.25; rank p = 0.742), 6 mo (MD 2.43, 95% CrI -0.72 to 5.62; rank p = 0.581), 12 mo (MD 2.94, 95% CrI -0.26 to 6.12, rank p = 0.782), and 24 mo (MD 3.63, 95% CrI 0.14 to 7.11; rank p = 0.948), at which point statistical significance was reached. At time points up to 60 mo, there were no statistically significant comparisons for other interventions. Analyses were not possible at 18, 48, or 72 mo. β did not reach statistical significance in meta-regression. τ2 was highest at 1 mo (0.56) and 60 mo (0.55). CONCLUSIONS: PUL ranked highly and resulted in erectile function improvement at 24 mo compared to mTURP, but direct evidence is lacking. We did not observe significant differences in erectile function following other interventions up to 60 mo. Owing to heterogeneity, our conclusions are weakest at 1 and 60 mo. Further RCTs comparing sexual function outcomes are recommended, such as PUL versus holmium laser or bipolar enucleation. PATIENT SUMMARY: Different surgical treatments can be used to treat benign enlargement of the prostate causing urinary problems. We compared the effects of various treatments on erectile function at time points up to 5 years after surgery. Compared to surgical removal of some of the prostate gland (transurethral resection of the prostate, TURP), a technique called prostatic urethral lift resulted in better erectile function scores at 24 months. However, other treatments did not differ in their effect on erectile function.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Light A, Jabarkhyl D, Gilling P, et al. Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Eur Urol. 2021. PMID: 34127315. doi:10.1016/j.eururo.2021.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。